Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 14/20 | 0.49 |
| ▸ | RARB | P10826 | 11/20 | 0.49 |
| ▸ | RXRB | P28702 | 10/20 | 0.49 |
| ▸ | RARG | P13631 | 10/20 | 0.49 |
| ▸ | RXRG | P48443 | 6/20 | 0.49 |
| ▸ | RARA | P10276 | 7/20 | 0.46 |
| ▸ | CYP26A1 | O43174 | 3/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | CRABP2 | P29373 | 1/20 | 0.45 |
| ▸ | CYP26B1 | Q9NR63 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1360287 | 0.77 | RXRA (0.49) | RXRARARBRXRBRARGRXRG | |
| SCHEMBL30701838 | 0.77 | RXRA (0.49) | RXRARARBRXRBRARGRXRG | |
| SCHEMBL9159319 | 0.76 | RARG (0.73) | RXRARARBRXRBRARGRXRG | |
| SCHEMBL24259941 | 0.75 | RARB (0.30) | RXRARARBRXRBRARGRXRG | |
| SCHEMBL29606831 | 0.74 | RXRA (0.46) | RXRARARBRXRBRARGRXRG | |
| SCHEMBL1615553 | 0.74 | RXRA (0.46) | RXRARARBRXRBRARGRXRG | |
| SCHEMBL11599145 | 0.74 | RXRA (0.42) | RXRARARBRXRBRARGRXRG | |
| SCHEMBL31145722 | 0.73 | RXRA (0.33) | RXRARARBRXRBRARGRXRG | |
| SCHEMBL3169358 | 0.73 | HTR2A (0.46) | RXRARARBRXRBRARGRXRG | |
| SCHEMBL16993773 | 0.73 | RXRA (0.69) | RXRARARBRXRBRARGRXRG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250368891-A1 | COMPOUND AND ORGANIC LIGHT-EMITTING ELEMENT COMPRISING SAME | LG CHEMICAL LTD (KR) | 2025-12-04 | — | — | US | disclosed |
| WO-2024196172-A1 | COMPOUND AND ORGANIC LIGHT-EMITTING ELEMENT COMPRISING SAME | 주식회사 엘지화학 | 2024-09-26 | — | — | WO | disclosed |
| US-20240025933-A1 | ORGANOMETALLIC COMPOUND AND ORGANIC LIGHT-EMITTING DIODE INCLUDING THE SAME | LG DISPLAY CO., LTD. (KR) | 2024-01-25 | — | — | US | disclosed |
| US-20240025933-A1 | ORGANOMETALLIC COMPOUND AND ORGANIC LIGHT-EMITTING DIODE INCLUDING THE SAME | LG DISPLAY CO., LTD. (KR) | 2024-01-25 | — | — | US | disclosed |
| US-20240025933-A1 | ORGANOMETALLIC COMPOUND AND ORGANIC LIGHT-EMITTING DIODE INCLUDING THE SAME | LG DISPLAY CO., LTD. (KR) | 2024-01-25 | — | — | US | disclosed |
| US-11364220-B2 | Compounds and methods for inhibiting CPY26 enzymes | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2022-06-21 | — | — | US | disclosed |
| US-20210220326-A1 | Compounds and Methods for Inhibiting CPY26 Enzymes | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2021-07-22 | — | — | US | disclosed |
| EP-2874999-B1 | NOVEL SELECTIVE COMPOUNDS INHIBITING CYP26A1 USEFUL IN COSMETIC AND PHARMACEUTICAL COMPOSITIONS | GALDERMA RES & DEV (FR) | 2016-08-24 | — | — | EP | disclosed |
| EP-2874999-B1 | NOVEL SELECTIVE COMPOUNDS INHIBITING CYP26A1 USEFUL IN COSMETIC AND PHARMACEUTICAL COMPOSITIONS | GALDERMA RES & DEV (FR) | 2016-08-24 | — | — | EP | disclosed |
| US-9408793-B2 | Selective compounds inhibiting CYP26A1 useful in cosmetic and pharmaceutical compositions | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2016-08-09 | — | — | US | disclosed |
| EP-0915823-A1 | BI-AROMATIC COMPOUNDS, PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING SAME AND USES | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA - CIRD GALDERMA (FR) | 1999-05-19 | — | — | EP | disclosed |
| US-5766610-A | USEFUL FOR TREATMENT OF MAMMALIAN SKIN AND HAIR, RHEUMATISM, RESIPIRATORY SYSTEM DISORDER, CARDIOVASCULAR AND VISION DISORDERS | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (FR) | 1998-06-16 | — | — | US | disclosed |
| US-5763487-A | SKIN DISORDERS, CARDIOVASCULAR DISORDERS AND COSMETICS | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (FR) | 1998-06-09 | — | — | US | disclosed |
| WO-1998022423-A1 | BI-AROMATIC COMPOUNDS, PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING SAME AND USES | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (C.I.R.D. GALDERMA) (FR) | 1998-05-28 | — | — | WO | disclosed |
| EP-0679630-B1 | Bicyclic aromatic compounds, pharmaceutical and cosmetic compositions containing them and uses | CIRD GALDERMA (FR) | 1998-05-06 | — | — | EP | disclosed |
| US-5672710-A | SPECIFIC AGONISTS FOR THE RXR RETINOID RECEPTOR RATHER THAN THE RAR ONE; SIDE EFFECT REDUCTION; SKIN AND NERVOUS SYTEM DISORDERS; ANTICARCINOGENIC AGENTS; VISION DEFECTS | ALLERGAN (US) | 1997-09-30 | — | — | US | disclosed |
| EP-0722928-B1 | Bicyclic-aromatic compounds with strong biologic activity, pharmaceutical and cosmetic compositions containing them and uses thereof | CIRD GALDERMA (FR) | 1997-08-06 | — | — | EP | disclosed |
| WO-1997016422-A1 | SULFIDES, SULFOXIDES AND SULFONES DISUBSTITUTED WITH A TETRAHYDRONAPHTHALENYL, CHROMANYL, THIOCHROMANYL OR TETRAHYDROQUINOLINYL AND SUBSTITUTED PHENYL OR HETEROARYL GROUP, HAVING RETINOID-LIKE BIOLOGICAL ACTIVITY | ALLERGAN (US) | 1997-05-09 | — | — | WO | disclosed |
| EP-0722928-A1 | Bicyclic-aromatic compounds with strong biologic activity, pharmaceutical and cosmetic compositions containing them and uses thereof | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (C.I.R.D. GALDERMA) (FR) | 1996-07-24 | — | — | EP | disclosed |
| EP-0679630-A1 | Bicyclic aromatic compounds, pharmaceutical and cosmetic compositions containing them and uses | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (C.I.R.D. GALDERMA) (FR) | 1995-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11364220-B2 | Compounds and methods for inhibiting CPY26 enzymes | CYP2A6, CYP27A1, CYP26B1 | RXRA 37/4885RARB 34/4885RXRB 49/4885 |
| US-20240025933-A1 | ORGANOMETALLIC COMPOUND AND ORGANIC LIGHT-EMITTING DIODE INCLUDING THE SAME | ODC1, OXA1L, LRRK2 | RXRA 869/4885RARB 468/4885RXRB 748/4885 |
| US-20210220326-A1 | Compounds and Methods for Inhibiting CPY26 Enzymes | CYP2A6, CYP27A1, CYP26B1 | RXRA 24/4885RARB 23/4885RXRB 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.